Pfizer (PFE) Stock Forecast, Price Target & Predictions
PFE Stock Forecast
Pfizer stock forecast is as follows: an average price target of $44.76 (represents a 78.11% upside from PFE’s last price of $25.13) and a rating consensus of 'Hold', based on 21 wall street analysts offering a 1-year stock forecast.
PFE Price Target
The average price target for Pfizer (PFE) is $44.76 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $20.00. This represents a potential 78.11% upside from PFE's last price of $25.13.
PFE Analyst Ratings
According to 21 Wall Street analysts, Pfizer's rating consensus is 'Hold'. The analyst rating breakdown for PFE stock is 1 'Strong Buy' (4.76%), 8 'Buy' (38.10%), 11 'Hold' (52.38%), 1 'Sell' (4.76%), and 0 'Strong Sell' (0.00%).
Pfizer Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Chris Shibutani | Goldman Sachs | - | - | 15.95% | 31.32% |
| Oct 17, 2024 | Courtney Breen | Bernstein | - | - | 7.85% | 27.34% |
| Sep 25, 2024 | Carter Gould | Barclays | - | - | 10.61% | 27.34% |
| Aug 07, 2024 | Narumi Nakagiri | Daiwa | - | - | 17.85% | 35.30% |
| Jul 31, 2024 | Mohit Bansal | Wells Fargo | - | - | -4.43% | 19.38% |
| Jul 31, 2024 | Chris Shibutani | Goldman Sachs | - | - | 8.31% | 35.30% |
| Jul 30, 2024 | Vamil Divan | Guggenheim | - | - | 17.19% | 43.26% |
| Jul 10, 2024 | Carter Gould | Barclays | - | - | 8.23% | 19.38% |
| May 22, 2024 | Evan Seigerman | BMO Capital | - | - | 21.62% | 43.26% |
| Feb 14, 2024 | Louise Chen | Cantor Fitzgerald | - | - | 66.85% | 79.07% |
The latest Pfizer stock forecast, released on Oct 30, 2024 by Chris Shibutani from Goldman Sachs, set a price target of $33.00, which represents a 15.95% increase from the stock price at the time of the forecast ($28.46), and a 31.32% increase from PFE last price ($25.13).
Pfizer Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 12 |
| Avg Price Target | $33.00 | $32.33 | $33.25 |
| Last Closing Price | $25.13 | $25.13 | $25.13 |
| Upside/Downside | 31.32% | 28.65% | 32.31% |
In the current month, the average price target of Pfizer stock is $33.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 31.32% increase as opposed to Pfizer's last price of $25.13. This month's average price target is up 2.07% compared to last quarter, and down -0.75% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Oct 23, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Oct 17, 2024 | Bernstein | Market Perform | Initialise | |
| Sep 25, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Sep 20, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Sep 20, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Sep 13, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 31, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Jul 31, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 31, 2024 | Goldman Sachs | Buy | Buy | Hold |
Pfizer's last stock rating was published by Goldman Sachs on Oct 30, 2024. The company gave PFE a "Buy" rating, the same as its previous rate.
Pfizer Financial Forecast
Pfizer Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $13.23B | $12.73B | $18.28B | $24.29B | $22.64B | $27.74B | $25.66B | $23.64B | $24.09B | $18.98B | $14.58B | $5.95B | $12.13B | $11.80B | $12.03B | $12.69B | $12.68B | $13.26B | $13.12B | $12.91B | $12.78B |
| Avg Forecast | $20.50B | $15.49B | $14.32B | $14.76B | $17.43B | $14.92B | $12.96B | $13.87B | $14.37B | $13.34B | $13.36B | $16.61B | $24.38B | $21.07B | $25.49B | $24.10B | $24.16B | $22.58B | $18.71B | $13.65B | $11.67B | $12.31B | $11.54B | $11.81B | $12.61B | $12.26B | $13.40B | $12.99B | $12.57B | $12.41B |
| High Forecast | $20.96B | $15.84B | $14.64B | $15.09B | $17.84B | $14.93B | $12.96B | $13.87B | $14.77B | $14.85B | $13.66B | $16.98B | $24.93B | $21.07B | $25.49B | $24.10B | $24.16B | $22.58B | $18.71B | $13.65B | $11.67B | $12.31B | $11.54B | $11.81B | $12.61B | $12.26B | $13.40B | $12.99B | $15.08B | $14.89B |
| Low Forecast | $19.64B | $14.84B | $13.72B | $14.14B | $16.98B | $14.91B | $12.96B | $13.87B | $14.13B | $12.24B | $12.80B | $15.91B | $23.36B | $21.07B | $25.49B | $24.10B | $24.16B | $22.58B | $18.71B | $13.65B | $11.67B | $12.31B | $11.54B | $11.81B | $12.61B | $12.26B | $13.40B | $12.99B | $10.06B | $9.93B |
| # Analysts | 1 | 1 | 1 | 1 | 11 | 5 | 3 | 3 | 6 | 10 | 8 | 8 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 0.95% | 1.10% | 1.00% | 1.07% | 1.09% | 1.06% | 0.98% | 1.07% | 1.01% | 1.07% | 0.51% | 0.99% | 1.02% | 1.02% | 1.01% | 1.03% | 0.99% | 1.01% | 1.03% | 1.03% |
Pfizer's average Quarter revenue forecast for Dec 23 based on 6 analysts is $14.37B, with a low forecast of $14.13B, and a high forecast of $14.77B. PFE's average Quarter revenue forecast represents a 8.59% increase compared to the company's last Quarter revenue of $13.23B (Sep 23).
Pfizer EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 11 | 5 | 3 | 3 | 6 | 10 | 8 | 8 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-803.00M | $4.21B | $8.40B | $7.56B | $11.25B | $13.31B | $11.52B | $5.32B | $9.50B | $8.25B | $7.24B | $1.42B | $3.85B | $5.57B | $5.48B | $282.00M | $12.69B | $6.05B | $6.22B | $5.99B | $5.81B |
| Avg Forecast | $6.68B | $5.05B | $4.67B | $4.81B | $5.68B | $4.86B | $4.22B | $7.96B | $4.68B | $4.35B | $4.36B | $8.52B | $3.63B | $7.09B | $8.58B | $9.11B | $8.13B | $7.60B | $6.30B | $5.74B | $3.93B | $4.14B | $3.89B | $4.96B | $4.24B | $4.13B | $4.51B | $5.39B | $5.83B | $5.63B |
| High Forecast | $6.83B | $5.16B | $4.77B | $4.92B | $5.82B | $4.87B | $4.22B | $9.56B | $4.81B | $4.84B | $4.45B | $10.22B | $4.35B | $7.09B | $8.58B | $10.93B | $8.13B | $7.60B | $6.30B | $6.89B | $3.93B | $4.14B | $3.89B | $5.95B | $4.24B | $4.13B | $4.51B | $6.47B | $7.00B | $6.76B |
| Low Forecast | $6.40B | $4.84B | $4.47B | $4.61B | $5.53B | $4.86B | $4.22B | $6.37B | $4.61B | $3.99B | $4.17B | $6.81B | $2.90B | $7.09B | $8.58B | $7.29B | $8.13B | $7.60B | $6.30B | $4.59B | $3.93B | $4.14B | $3.89B | $3.97B | $4.24B | $4.13B | $4.51B | $4.31B | $4.67B | $4.51B |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.18% | 0.97% | 0.99% | 2.08% | 1.59% | 1.55% | 1.26% | 0.65% | 1.25% | 1.31% | 1.26% | 0.36% | 0.93% | 1.43% | 1.11% | 0.07% | 3.07% | 1.34% | 1.15% | 1.03% | 1.03% |
10 analysts predict PFE's average Quarter EBITDA for Sep 23 to be $4.35B, with a high of $4.84B and a low of $3.99B. This is 3.28% upper than Pfizer's previous annual EBITDA (Jun 23) of $4.21B.
Pfizer Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 11 | 5 | 3 | 3 | 6 | 10 | 8 | 8 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | $-2.38B | $2.33B | $5.54B | $5.00B | $8.61B | $9.91B | $7.86B | $3.85B | $8.15B | $5.56B | $4.88B | $594.00M | $2.19B | $3.43B | $3.40B | $-336.00M | $7.68B | $5.05B | $3.88B | $3.56B | $3.12B |
| Avg Forecast | $6.21B | $3.78B | $3.37B | $4.28B | $2.74B | $3.51B | $2.61B | $5.94B | $-902.76M | $-455.48M | $3.25B | $6.35B | $2.31B | $7.90B | $9.82B | $6.79B | $4.98B | $6.13B | $5.53B | $3.86B | $2.87B | $4.07B | $3.85B | $3.07B | $3.28B | $3.52B | $4.29B | $3.37B | $3.47B | $3.03B |
| High Forecast | $6.39B | $3.89B | $3.46B | $4.41B | $3.43B | $3.58B | $2.61B | $7.13B | $-475.14M | $-313.14M | $3.35B | $7.62B | $2.78B | $8.23B | $9.82B | $8.15B | $4.98B | $6.13B | $5.64B | $4.64B | $2.87B | $4.07B | $3.85B | $3.69B | $3.28B | $3.52B | $4.29B | $4.04B | $4.16B | $3.63B |
| Low Forecast | $5.87B | $3.58B | $3.18B | $4.05B | $2.06B | $3.43B | $2.61B | $4.75B | $-1.33B | $-683.23M | $3.07B | $5.08B | $1.85B | $7.57B | $9.82B | $5.44B | $4.98B | $6.13B | $5.41B | $3.09B | $2.87B | $4.07B | $3.85B | $2.46B | $3.28B | $3.52B | $4.29B | $2.69B | $2.77B | $2.42B |
| Surprise % | - | - | - | - | - | - | - | - | - | 5.23% | 0.72% | 0.87% | 2.16% | 1.09% | 1.01% | 1.16% | 0.77% | 1.33% | 1.01% | 1.26% | 0.21% | 0.54% | 0.89% | 1.11% | -0.10% | 2.18% | 1.18% | 1.15% | 1.03% | 1.03% |
Pfizer's average Quarter net income forecast for Sep 23 is $-455.48M, with a range of $-683.23M to $-313.14M. PFE's average Quarter net income forecast represents a -119.57% decrease compared to the company's last Quarter net income of $2.33B (Jun 23).
Pfizer SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 11 | 5 | 3 | 3 | 6 | 10 | 8 | 8 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | $3.28B | $3.50B | $3.42B | $4.64B | $3.39B | $3.05B | $2.59B | $4.09B | $2.90B | $2.93B | $2.78B | $2.70B | $3.02B | $2.81B | $2.74B | $4.24B | $3.26B | $3.51B | $3.34B | $3.41B | $3.31B |
| Avg Forecast | $4.51B | $3.41B | $3.15B | $3.25B | $3.83B | $3.28B | $2.85B | $1.96B | $3.16B | $2.93B | $2.94B | $2.09B | $2.79B | $4.61B | $5.58B | $2.24B | $5.29B | $4.94B | $4.09B | $2.20B | $2.55B | $2.69B | $2.53B | $2.48B | $2.76B | $2.68B | $2.93B | $2.89B | $3.32B | $3.21B |
| High Forecast | $4.61B | $3.48B | $3.22B | $3.32B | $3.92B | $3.28B | $2.85B | $2.35B | $3.25B | $3.27B | $3.00B | $2.51B | $3.34B | $4.61B | $5.58B | $2.69B | $5.29B | $4.94B | $4.09B | $2.65B | $2.55B | $2.69B | $2.53B | $2.98B | $2.76B | $2.68B | $2.93B | $3.47B | $3.99B | $3.85B |
| Low Forecast | $4.32B | $3.26B | $3.02B | $3.11B | $3.73B | $3.28B | $2.85B | $1.57B | $3.11B | $2.69B | $2.82B | $1.68B | $2.23B | $4.61B | $5.58B | $1.79B | $5.29B | $4.94B | $4.09B | $1.76B | $2.55B | $2.69B | $2.53B | $1.98B | $2.76B | $2.68B | $2.93B | $2.32B | $2.66B | $2.57B |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.12% | 1.19% | 1.63% | 1.67% | 0.74% | 0.55% | 1.16% | 0.77% | 0.59% | 0.72% | 1.26% | 1.06% | 1.12% | 1.11% | 1.11% | 1.54% | 1.21% | 1.20% | 1.15% | 1.03% | 1.03% |
Pfizer's average Quarter SG&A projection for Dec 23 is $3.16B, based on 6 Wall Street analysts, with a range of $3.11B to $3.25B. The forecast indicates a -3.69% fall compared to PFE last annual SG&A of $3.28B (Sep 23).
Pfizer EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 11 | 5 | 3 | 3 | 6 | 10 | 8 | 8 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.42 | $0.41 | $0.98 | $0.89 | $1.54 | $1.77 | $1.40 | $0.69 | $1.45 | $0.99 | $0.87 | $0.11 | $0.39 | $0.62 | $0.61 | $-0.06 | $1.38 | $0.91 | $0.69 | $0.60 | $0.52 |
| Avg Forecast | $1.09 | $0.66 | $0.59 | $0.75 | $0.48 | $0.61 | $0.46 | $0.52 | $-0.16 | $-0.08 | $0.57 | $0.98 | $1.05 | $1.39 | $1.72 | $1.49 | $0.87 | $1.08 | $0.97 | $0.78 | $0.50 | $0.71 | $0.68 | $0.73 | $0.58 | $0.62 | $0.75 | $0.75 | $0.73 | $0.65 |
| High Forecast | $1.12 | $0.68 | $0.61 | $0.77 | $0.60 | $0.63 | $0.46 | $0.52 | $-0.08 | $-0.05 | $0.59 | $1.01 | $1.08 | $1.45 | $1.72 | $1.53 | $0.87 | $1.08 | $0.99 | $0.78 | $0.50 | $0.71 | $0.68 | $0.73 | $0.58 | $0.62 | $0.75 | $0.75 | $0.88 | $0.78 |
| Low Forecast | $1.03 | $0.63 | $0.56 | $0.71 | $0.36 | $0.60 | $0.46 | $0.51 | $-0.23 | $-0.12 | $0.54 | $0.93 | $0.99 | $1.33 | $1.72 | $1.46 | $0.87 | $1.08 | $0.95 | $0.78 | $0.50 | $0.71 | $0.68 | $0.73 | $0.58 | $0.62 | $0.75 | $0.75 | $0.58 | $0.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | 5.26% | 0.72% | 1.00% | 0.85% | 1.11% | 1.03% | 0.94% | 0.79% | 1.35% | 1.02% | 1.12% | 0.22% | 0.55% | 0.92% | 0.83% | -0.10% | 2.23% | 1.21% | 0.92% | 0.82% | 0.80% |
According to 10 Wall Street analysts, Pfizer's projected average Quarter EPS for Sep 23 is $-0.08, with a low estimate of $-0.12 and a high estimate of $-0.05. This represents a -119.47% decrease compared to PFE previous annual EPS of $0.41 (Jun 23).